Roivant Preps Brepocitinib Launch Amid $950M Moderna Payout
Event summary
- Roivant targets September 2026 launch for brepocitinib in dermatomyositis, with Phase 3 data in non-infectious uveitis due by year-end.
- Genevant and Arbutus received $950M from Moderna in July 2026 under a $2.25B settlement, with additional $1.3B contingent on litigation outcomes.
- Roivant's cash position stands at $3.9B as of June 30, 2026, excluding the Moderna payment.
- Phase 3 trial for brepocitinib in cutaneous sarcoidosis begins enrollment, with topline data expected in 2028.
The big picture
Roivant is positioning itself for a pivotal year with multiple clinical readouts and commercial milestones. The $950M Moderna payout bolsters its cash runway, but success hinges on executing across its diverse pipeline while navigating ongoing litigation. The biopharma's ability to monetize its assets through both therapeutic launches and IP enforcement will shape its trajectory.
What we're watching
- Commercial Execution
- Whether Roivant can successfully launch brepocitinib in dermatomyositis and expand into other indications.
- Litigation Outcomes
- The pace at which Genevant's additional $1.3B from Moderna materializes, contingent on Section 1498 appeal resolution.
- Pipeline Progress
- How Immunovant's IMVT-1402 and Pulmovant's mosliciguat trials advance, with key readouts due in late 2026.